Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

This study has been completed.
Information provided by:
Penwest Pharmaceuticals Co. Identifier:
First received: December 17, 2009
Last updated: April 21, 2011
Last verified: April 2011

This is a Phase 2a double-blind, placebo-controlled study with two dose levels of A0001 given twice daily for 28 days. Potential subjects will be screened first to determine eligibility, after which they will be randomized to receive either a high dose of A0001, a low dose of A0001 or placebo for 28 days.

Eligible subjects will return within 21 days of screening for the baseline visit and randomization to one of three potential treatments. The subjects will be required to take 3 capsules of study medication in the morning with a morning meal and 3 capsules of study medication at night with an evening meal for 28 days. Additional visits to the clinic are planned for Day 14 and Day 28, at which time a number of clinical and biochemical assessments will be done.

Condition Intervention Phase
Friedreich's Ataxia
Drug: alpha-tocopherolquinone (A0001)
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia

Resource links provided by NLM:

Further study details as provided by Penwest Pharmaceuticals Co.:

Primary Outcome Measures:
  • Change in Disposition Index of Glucose Regulation, determined by Frequent Sampling IV Glucose Tolerance Test [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Sensitivity index (SI) calculated from IVGTT [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • Glucose effectiveness (SG) calculated from IVGTT [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • AIRg for glucose and insulin during IVGTT [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • Fasting Glucose, Insulin and Lactate [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • HbA1C [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • Plasma 1,5-anhydroglucitol (1,5-AG) (Glycomark) [ Time Frame: Baseline, Day 14 and Day28 ] [ Designated as safety issue: No ]
  • Specific Activity of Complex 1 in whole blood [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • Timed 25 Foot Walk Test [ Time Frame: Baseline and Day 28 ] [ Designated as safety issue: No ]
  • FARS/neurological exam [ Time Frame: Baseline and Day 28 ] [ Designated as safety issue: No ]
  • 9-Hole Peg Test [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • Vision Low Contrast Letter Acuity Test [ Time Frame: Baseline and Day 28 ] [ Designated as safety issue: No ]
  • Global Impression of Clinical Severity [ Time Frame: Baseline, Day 14 and Day 28 ] [ Designated as safety issue: No ]
  • Modified Fatigue Impact Scale [ Time Frame: Baseline and Day 28 ] [ Designated as safety issue: No ]
  • Activities of Daily Living [ Time Frame: Baseline and Day 28 ] [ Designated as safety issue: No ]
  • SF-36® [ Time Frame: Baseline and Day 28 ] [ Designated as safety issue: No ]

Estimated Enrollment: 42
Study Start Date: December 2009
Study Completion Date: March 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low Dose
A0001 (0.5 g BID)
Drug: alpha-tocopherolquinone (A0001)
28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
Experimental: High Dose
A0001 (0.75 g BID)
Drug: alpha-tocopherolquinone (A0001)
28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
Placebo Comparator: Placebo
Drug: placebo
28 days of placebo oral capsules. Treatment taken twice daily with meals.


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Individuals with genetically confirmed Friedreich's Ataxia (GAA or point mutation)
  • Impaired Glucose Tolerance, measured by Oral GTT

Exclusion Criteria:

  • Overt Diabetes Mellitus
  • Presence of clinically significant cardiovascular disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01035671

United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Penwest Pharmaceuticals Co.
Principal Investigator: David Lynch, MD, PhD Children's Hospital of Philadelphia
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Thomas Sciascia, MD/Chief Medical Officer and VP Clinical Operations and Regulatory Affairs, Penwest Pharmaceuticals Co. Identifier: NCT01035671     History of Changes
Other Study ID Numbers: FRD02 
Study First Received: December 17, 2009
Last Updated: April 21, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cerebellar Ataxia
Friedreich Ataxia
Brain Diseases
Central Nervous System Diseases
Cerebellar Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Metabolic Diseases
Mitochondrial Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Spinal Cord Diseases
Spinocerebellar Degenerations
Vitamin E
Antihypertensive Agents
Growth Substances
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents
Vitamins processed this record on May 23, 2016